MX2009012331A - Compuesto carbamoiloxiarilalcanoilarilpiperazina novedoso, composiciones farmaceuticas que comprenden el compuesto y metodo para el tratamiento de dolor, ansiedad y depresion mediante la administracion del compuesto. - Google Patents

Compuesto carbamoiloxiarilalcanoilarilpiperazina novedoso, composiciones farmaceuticas que comprenden el compuesto y metodo para el tratamiento de dolor, ansiedad y depresion mediante la administracion del compuesto.

Info

Publication number
MX2009012331A
MX2009012331A MX2009012331A MX2009012331A MX2009012331A MX 2009012331 A MX2009012331 A MX 2009012331A MX 2009012331 A MX2009012331 A MX 2009012331A MX 2009012331 A MX2009012331 A MX 2009012331A MX 2009012331 A MX2009012331 A MX 2009012331A
Authority
MX
Mexico
Prior art keywords
compound
anxiety
depression
treating pain
administering
Prior art date
Application number
MX2009012331A
Other languages
English (en)
Inventor
Han-Ju Yi
Byong Sung Kwak
Hong Sik Moon
Young Soon Kang
Dae Joong Im
Eun Hee Chae
Sang Mi Chae
Ki Ho Lee
Original Assignee
Sk Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Holdings Co Ltd filed Critical Sk Holdings Co Ltd
Publication of MX2009012331A publication Critical patent/MX2009012331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Se proporciona un novedoso compuesto derivado de carbamoiloxi arilacanoil arilpiperazina que tiene abundantes características racémicas o enantioméricas, representado por la fórmula I, y sales o hidratos del mismo farmacéuticamente disponibles; también se proporciona una composición farmacéutica para el tratamiento del dolor, la ansiedad o la depresión que incluye una cantidad efectiva del compuesto, y un método para tratar el dolor, la ansiedad o la depresión en mamíferos con la administración de una cantidad efectiva del compuesto a los mamíferos que tengan necesidad del tratamiento de los mismos.
MX2009012331A 2007-05-14 2008-04-30 Compuesto carbamoiloxiarilalcanoilarilpiperazina novedoso, composiciones farmaceuticas que comprenden el compuesto y metodo para el tratamiento de dolor, ansiedad y depresion mediante la administracion del compuesto. MX2009012331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070046708 2007-05-14
PCT/KR2008/002470 WO2008140198A1 (en) 2007-05-14 2008-04-30 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Publications (1)

Publication Number Publication Date
MX2009012331A true MX2009012331A (es) 2010-02-10

Family

ID=40002366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012331A MX2009012331A (es) 2007-05-14 2008-04-30 Compuesto carbamoiloxiarilalcanoilarilpiperazina novedoso, composiciones farmaceuticas que comprenden el compuesto y metodo para el tratamiento de dolor, ansiedad y depresion mediante la administracion del compuesto.

Country Status (18)

Country Link
US (3) US8541409B2 (es)
EP (2) EP2150550B1 (es)
JP (2) JP5605569B2 (es)
KR (2) KR101451799B1 (es)
CN (2) CN101679400B (es)
AT (1) ATE538104T1 (es)
AU (1) AU2008251259B2 (es)
BR (1) BRPI0811245B1 (es)
CA (2) CA2686547C (es)
DK (1) DK2155736T3 (es)
ES (2) ES2379848T3 (es)
HK (1) HK1141019A1 (es)
MX (1) MX2009012331A (es)
PL (1) PL2155736T3 (es)
PT (1) PT2155736E (es)
RU (1) RU2460731C2 (es)
WO (2) WO2008140198A1 (es)
ZA (1) ZA200907956B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379848T3 (es) * 2007-05-14 2012-05-04 Sk Biopharmaceuticals Co., Ltd. Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto
US8101642B2 (en) 2008-06-05 2012-01-24 Sk Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
EP2285787B1 (en) * 2008-06-05 2015-08-26 SK Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
KR101386679B1 (ko) * 2009-07-10 2014-04-17 주식회사 녹십자 신규한 아릴피페라진-함유 이미다졸 4-카복사마이드 유도체 및 이를 포함하는 약학 조성물
KR101810975B1 (ko) 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
AU2013277154A1 (en) 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof
JP7369185B2 (ja) * 2018-10-19 2023-10-25 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物の糖尿病性末梢神経障害又は化学療法剤誘発性末梢神経障害の予防、緩和又は治療のための使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135756A (en) * 1964-06-02 Table ii
US3002976A (en) 1959-10-12 1961-10-03 Paul A J Janssen 1-(2-thienyl)-omega-(4-arylpiperazine)alkanols
DE2325633A1 (de) * 1973-05-21 1974-12-12 Boehringer Sohn Ingelheim Piperazinderivate
NL8202636A (nl) * 1982-06-29 1984-01-16 Gist Brocades Nv Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
JPS6175A (ja) * 1984-03-06 1986-01-06 ブリストル−マイア−ズ　コムパニ− 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体
US4605655A (en) 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
ES2140374T3 (es) 1989-04-22 2000-03-01 American Home Prod Derivados de piperazina funcionalizados con alquilos terciarios.
KR0173310B1 (ko) * 1989-04-22 1999-02-01 폴 에이 리쳐 피페라진 유도체
US5364849A (en) 1989-04-22 1994-11-15 John Wyeth & Brother, Limited 1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
WO1998039324A1 (en) * 1997-03-07 1998-09-11 Takeda Chemical Industries, Ltd. 2-peperazinone-1-acetic acid derivatives and their use
ES2128266B1 (es) * 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19934433A1 (de) 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
ITMI20021327A1 (it) * 2002-06-14 2003-12-15 Recordati Chem Pharm Nuove ossialchilpiperazine
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
AU2004283313A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. TAO kinase modulators and methods of use
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
BRPI0715341A2 (pt) 2006-08-17 2013-11-26 Hoffmann La Roche Derivados de aril piperazina e usos dos mesmos
ES2379848T3 (es) 2007-05-14 2012-05-04 Sk Biopharmaceuticals Co., Ltd. Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
WO2008140198A1 (en) 2008-11-20
EP2155736A4 (en) 2010-11-10
WO2008140197A1 (en) 2008-11-20
EP2150550A4 (en) 2010-11-10
CA2686926C (en) 2016-01-05
US20100160331A1 (en) 2010-06-24
ATE538104T1 (de) 2012-01-15
CA2686926A1 (en) 2008-11-20
KR101468553B1 (ko) 2014-12-09
US20110195963A1 (en) 2011-08-11
CN101679399B (zh) 2013-11-06
BRPI0811245A2 (pt) 2014-11-04
EP2155736A1 (en) 2010-02-24
PT2155736E (pt) 2012-03-28
JP2010526870A (ja) 2010-08-05
CN101679400A (zh) 2010-03-24
EP2155736B1 (en) 2011-12-21
CN101679399A (zh) 2010-03-24
KR20080100765A (ko) 2008-11-19
JP5605569B2 (ja) 2014-10-15
AU2008251259A1 (en) 2008-11-20
CN101679400B (zh) 2013-04-17
US20120095007A2 (en) 2012-04-19
ES2379848T3 (es) 2012-05-04
RU2460731C2 (ru) 2012-09-10
KR20080100766A (ko) 2008-11-19
PL2155736T3 (pl) 2012-09-28
EP2150550A1 (en) 2010-02-10
AU2008251259B2 (en) 2013-02-14
EP2150550B1 (en) 2013-02-27
US20140088095A1 (en) 2014-03-27
JP5387917B2 (ja) 2014-01-15
US8541409B2 (en) 2013-09-24
KR101451799B1 (ko) 2014-10-16
US8901116B2 (en) 2014-12-02
ES2402173T3 (es) 2013-04-29
JP2010526871A (ja) 2010-08-05
ZA200907956B (en) 2011-01-26
BRPI0811245B1 (pt) 2021-05-25
DK2155736T3 (da) 2012-03-12
CA2686547A1 (en) 2008-11-20
CA2686547C (en) 2015-12-08
US8815852B2 (en) 2014-08-26
HK1141019A1 (en) 2010-10-29
RU2009146132A (ru) 2011-06-20

Similar Documents

Publication Publication Date Title
HK1141019A1 (en) Carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2009011867A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
SG10201806714PA (en) C7-fluoro substituted tetracycline compounds
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
TW200806299A (en) Treatment of pain
MX2009011601A (es) Agentes terapeuticos utiles para tratar el dolor.
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
MX2007006082A (es) Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
MY151072A (en) Heteroaryl derivative
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights